ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

US High Court Invalidates Prometheus Patents On Medical Diagnostic Tests

By Brent Kendall Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Supreme Court on Tuesday invalidated two Prometheus Laboratories Inc. patents for a test that helps doctors set drug dosages for patients with Crohn's disease. The case was considered a key test of how far companies can go in patenting medical diagnostic tests, which can be used to screen patients for diseases and test whether a person can benefit from a particular treatment. The high court, in a unanimous ruling by Justice Stephen Breyer, said the patents were invalid because they made claims on laws of nature, which aren't patentable. The ruling was a win for the Mayo Clinic, which wants to offer a competing medical test. Mayo argued the Prometheus patents improperly sought to claim a patent monopoly on the right to observe a natural phenomenon: how the human body reacts to ingesting certain drugs. Leading medical groups supported Mayo in the case, arguing that no one should enjoy exclusive patent rights to tests that observe the human body's natural response to illness or treatments. The ruling was a setback for biotechnology and drug companies such as Roche Holding AG (RHHBY, ROG.VX) and Abbott Laboratories (ABT), which argued that such patents are key to protecting investments in medical advances. Prometheus is a unit of Nestle S.A. (NSRGY, NESN.VX). Among the best known of the patents are those held by Myriad Genetics Inc. (MYGN) that allow the company to be the exclusive provider of screening tests that identify patients at risk for breast and ovarian cancers. Those patents are also being challenged in court. The case is Mayo Collaborative Services v. Prometheus Laboratories Inc., 10-1150. --By Brent Kendall, Dow Jones Newswires; 202-862-9222;

Stock News for Abbott Labs (ABT)
11/05/201514:41:24Quarterly Report (10-q)
11/03/201508:30:00Zoetis Lifts Outlook as Results Top Views
11/01/201511:23:035 Healthcare Trends to Invest in for the Next 20 Years
10/30/201512:31:00Health is a Marathon, not a Sprint
10/29/201515:52:00'Science' Says Abbott Is a Top Employer
10/28/201519:52:56Your One-Stop Dividend Aristocrat Resource
10/23/201502:04:49The Conservative Total Return Portfolio: 3 Hits And A Miss
10/22/201508:01:00Abbott fait équipe avec Cristiano Ronaldo, star du football...
10/22/201508:01:00Abbott Teams Up with Soccer Star Cristiano Ronaldo to Inspire...
10/22/201508:01:00Abbott Teams Up with Soccer Star Cristiano Ronaldo to Inspire...
10/21/201519:49:00Abbott Teams Up with Football Star Cristiano Ronaldo to Inspire...
10/21/201511:10:00Abbott Labs Profit Rises
10/21/201510:50:00Abbott Labs Profit Rises, Helped by Emerging Markets
10/21/201507:45:00Abbott Reports Third-Quarter 2015 Results
10/20/201517:30:59Notable earnings before Wednesday’s open
10/16/201501:40:00Valeant Probe Reprises Federal Focus on Drug Pricing
10/15/201510:00:00New York Road Runners and Abbott Partner for 2015 TCS New York...
10/12/201516:00:00Abbott Laboratories Dissolving Stent Shows Mixed Results
10/12/201515:57:00Abbott Laboratories Dissolving Stent Shows Mixed Results in Study
10/12/201514:25:00Abbott Announces Positive Clinical Results of Absorb™, the N...

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations